Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Clinical and economic impact of five-year adherence to disease-modifying therapies in a commercially insured multiple sclerosis population.
Glial influences on BBB functions and molecular players in immune cell trafficking.
Back and forth in time: Directing age in iPSC-derived lineages.
Increased cerebrospinal fluid osteopontin levels and its involvement in macrophage infiltration in neuromyelitis optica.
Brain iron accumulation affects myelin-related molecular systems implicated in a rare neurogenetic disease family with neuropsychiatric features.
Infodemiology and infoveillance of multiple sclerosis in Italy.
Effects of walking direction and cognitive challenges on gait in persons with multiple sclerosis.
Thalamo-striato-cortical determinants to fatigue in multiple sclerosis.
Increased CXCL10 expression in MS MSCs and monocytes is unaffected by AHSCT.
Conclusion: National incidence and risk factor assessments may become a basis for the evaluation of prevention trials - prospects from the Third Nordic MS Symposium.
Effect of ether glycerol lipids on interleukin-1β release and experimental autoimmune encephalomyelitis.
In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand 11C-PK11195.
Clinical outcome measures in multiple sclerosis.
Kappa opioid receptor activation alleviates experimental autoimmune encephalomyelitis and promotes oligodendrocyte-mediated remyelination.
[Diagnostic criteria for neuromyelitisoptica spectrum disorders].
Clinical perspectives on medical marijuana (cannabis) for neurologic disorders.
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Medications Are Associated with Falls in People with Multiple Sclerosis: A Prospective Cohort Study.
[Anti-myelin oligodendrocyte glycoprotein (MOG) antibody].
Us Rrms Patient Preferences for Multiple Sclerosis Treatments: An Online Survey.
Myelin oligodendrocyte glycoprotein (MOG35-55)-induced experimental autoimmune encephalomyelitis is ameliorated in interleukin-32 alpha transgenic mice.
Association of myelin peptide with vitamin D prevents autoimmune encephalomyelitis development.
A literature review on optic neuritis following vaccination against virus infections.
Body Mass Index in Multiple Sclerosis: Associations with CSF Neurotransmitter Metabolite Levels.
Responsiveness of selected outcome measures of participation restriction and quality of life in patients with multiple sclerosis.
Pages
« first
‹ previous
…
663
664
665
666
667
668
669
670
671
…
next ›
last »